Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Pituitary Neoplasms × Temozolomide × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 8 Recurrence 3 Astrocytoma 3 Gliosarcoma 2 Spinal Cord Neoplasms 1 Pituitary Neoplasms 1 Oligodendroglioma 1 Non Small Cell Lung Cancer Metastatic 1 Melanoma 1 Medulloblastoma 1 Glioma 1 Ependymoma 1 Brain Neoplasms 1

Interventions

Temozolomide 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04244708 2020-01-28

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Peking Union Medical College Hospital

Phase 2/3 Unknown

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡